<p>Halozyme Therapeutics（纳斯达克股票代码：HALO - 获取免费报告）在周二发布的一份报告中，摩根士丹利的研究分析师将其目标价格从 96.00 美元下调至 93.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “增持” 评级。摩根士丹利的目标价格暗示该公司当前价格有 27.85% 的潜在上涨空间。</p>
<p>获取 <strong>Halozyme Therapeutics</strong> 的提醒：</p>
<p>其他一些研究公司也最近对 HALO 发表了看法。富国银行将 Halozyme Therapeutics 的股票目标价格从 65.00 美元上调至 75.00 美元，并在 2 月 19 日的研究报告中给予该股票 “持平” 评级。HC Wainwright 将 Halozyme Therapeutics 的股票目标价格从 90.00 美元上调至 95.00 美元，并在 4 月 29 日的研究报告中给予该股票 “买入” 评级。华尔街 Zen 在 2 月 21 日的研究报告中将 Halozyme Therapeutics 的股票评级从 “强力买入” 下调至 “持有”。TD Cowen 在 2 月 18 日的研究报告中重申了对 Halozyme Therapeutics 的 “买入” 评级。最后，Benchmark 在 2 月 19 日的研究报告中将 Halozyme Therapeutics 的股票目标价格从 75.00 美元上调至 90.00 美元，并给予该股票 “买入” 评级。六位股票研究分析师对该股票给予了 “买入” 评级，五位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，Halozyme Therapeutics 目前的平均评级为 “持有”，平均目标价格为 80.67 美元。</p>
<p><strong>查看我们关于 HALO 的最新研究报告</strong></p>
<h2>Halozyme Therapeutics 股票表现</h2>
<p>Halozyme Therapeutics 的股票在周二的午盘交易中上涨了 6.33 美元，达到了 72.74 美元。该公司交易了 2,175,469 股股票，而其平均交易量为 1,740,726 股。Halozyme Therapeutics 的 12 个月低点为 47.50 美元，12 个月高点为 82.22 美元。该公司的债务与股本比率为 43.89，速动比率为 3.66，流动比率为 4.66。该股票的市值为 86.2 亿美元，市盈率为 29.22，市盈增长比率为 0.26，贝塔值为 0.89。该公司的 50 日简单移动平均线为 65.68 美元，200 日简单移动平均线为 68.57 美元。</p>
<p>Halozyme Therapeutics（纳斯达克股票代码：HALO - 获取免费报告）最近于 5 月 11 日发布了季度财报。这家生物制药公司报告本季度每股收益为 1.60 美元，超出分析师一致预期的 1.54 美元，超出幅度为 0.06 美元。该公司本季度的收入为 3.7671 亿美元，而一致预期为 3.5860 亿美元。Halozyme Therapeutics 的净利润率为 22.69%，股本回报率为 136.12%。该公司的收入同比增长了 42.2%。在去年同期，该公司每股收益为 1.11 美元。Halozyme Therapeutics 已将其 2026 财年的指导目标设定为每股收益 7.750-8.250 美元。股票研究分析师预测 Halozyme Therapeutics 在当前年度将发布每股收益 7.68 美元。</p>
<h2>内部活动</h2>
<p>在其他新闻中，首席执行官 Helen Torley 在 4 月 2 日的交易中出售了 20,000 股 Halozyme Therapeutics 的股票。该股票以平均价格 64.24 美元出售，总价值为 1,284,800.00 美元。交易完成后，首席执行官直接持有该公司 767,780 股股票，价值约为 49,322,187.20 美元。此次交易使其持股减少了 2.54%。该交易已在向 SEC 提交的文件中披露，可以通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 Bernadette Connaughton 在 5 月 1 日的交易中出售了 1,625 股 Halozyme Therapeutics 的股票。该股票以平均价格 63.48 美元出售，总交易额为 103,155.00 美元。交易完成后，该董事直接持有该公司 38,498 股股票，价值为 2,443,853.04 美元。这笔交易使其持股减少了 4.05%。此次出售的披露信息可在 SEC 文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去三个月中，内部人士出售了价值 6,073,942 美元的 90,482 股公司股票。公司内部人士持有该公司股票的 2.50%。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金和其他机构投资者最近调整了对 Halozyme 的持股。Measured Wealth Private Client Group LLC 在第四季度将其在 Halozyme Therapeutics 的股份增加了 51.5%。Measured Wealth Private Client Group LLC 现在拥有 365 股该生物制药公司的股票，价值 25,000 美元，在此期间又购买了 124 股。Abel Hall LLC 在第四季度将其在 Halozyme Therapeutics 的股份提高了 4.2%。Abel Hall LLC 现在拥有 3,216 股该生物制药公司的股票，价值 216,000 美元，在上个季度又购买了 129 股。StoneX Group Inc. 在第四季度将其在 Halozyme Therapeutics 的股份提高了 3.8%。StoneX Group Inc. 现在拥有 3,650 股该生物制药公司的股票，价值 246,000 美元，在上个季度又购买了 132 股。Moran Wealth Management LLC 在第四季度将其在 Halozyme Therapeutics 的股份提高了 0.4%。Moran Wealth Management LLC 现在拥有 35,596 股该生物制药公司的股票，价值 2,396,000 美元，在上个季度又购买了 151 股。最后，Twin Capital Management Inc. 在第一季度将其在 Halozyme Therapeutics 的股份提高了 1.4%。Twin Capital Management Inc. 现在拥有 11,422 股该生物制药公司的股票，价值 738,000 美元，在上个季度又购买了 161 股。97.79% 的股票由机构投资者和对冲基金持有。</p>
<h2>更多 Halozyme Therapeutics 新闻</h2>
<p>以下是本周影响 Halozyme Therapeutics 的主要新闻：</p>
<ul>
<li>积极情绪：Halozyme 在第一季度的收入和收益均超出预期，收入同比增长 42%，约为 3.77 亿美元，EPS 为 1.60 美元，超出预期。HALOZYME 报告 2026 年第一季度业绩并重申 2026 年财务指引</li>
<li>积极情绪：该公司还宣布了一项新的 10 亿美元股票回购计划，并表示预计在 2026 年回购至少 4 亿美元的股票，显示出对现金流和未来表现的信心。HALOZYME 报告 2026 年第一季度业绩并重申 2026 年财务指引</li>
<li>中性情绪：Halozyme 重申了 2026 年的全年收入、调整后 EBITDA 和非 GAAP EPS 指引，这表明管理层仍然充满信心，但尽管业绩超出预期，仍未提高其前景。HALOZYME 报告 2026 年第一季度业绩并重申 2026 年财务指引</li>
<li>消极情绪：一些第三方摘要指出，稀释后的 EPS 低于某些预期，尽管收入强劲，这可能会抑制对本季度的热情。Halozyme Therapeutics, Inc. (HALO) 2026 年第一季度财报电话会议记录</li>
</ul>
<h2>Halozyme Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Halozyme Therapeutics, Inc. 是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，专注于新型药物输送技术的开发和商业化。成立于 1998 年，Halozyme 专注于通过其专有平台实现生物治疗的皮下给药。公司的核心使命是改善患者的获取和便利性，同时保持与传统给药途径相当或更好的疗效和安全性。</p>
<p>公司的旗舰技术 ENHANZE® 基于重组人透明质酸酶 PH20 (rHuPH20)，这是一种在细胞外基质中暂时降解透明质酸的酶。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Halozyme Therapeutics</li>
<li>Shake Shack 股票因业绩不及预期而受到冲击</li>
<li>On Holdings 为马拉松反弹做好准备：新高即将到来</li>
<li>DRAM 震荡：三星失足，美光追逐 1000 美元</li>
<li>MP Materials 正在悄然建立一个稀土强国</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SEFMTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SEFMTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Halozyme Therapeutics 吗？</h2>
<p>在你考虑 Halozyme Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Halozyme Therapeutics 并不在名单上。</p>
<p>虽然 Halozyme Therapeutics 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

奥洛兹美医疗

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

IBBQ

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>摩根士丹利已将 Halozyme Therapeutics（纳斯达克代码：HALO）的目标股价从 96.00 美元下调至 93.00 美元，同时维持 “增持” 评级。这个新目标暗示从当前价格来看有 27.85% 的潜在上涨空间。其他公司也调整了他们的评级，富国银行将目标价上调至 75.00 美元，HC Wainwright 则上调至 95.00 美元。Halozyme 的股票最近交易价格为 72.74 美元，市值为 86.2 亿美元，市盈率为 29.22。该公司报告了强劲的季度收益，收入同比增长 42.2%，超出预期</p>

<p>Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) had its target price reduced by research analysts at Morgan Stanley from $96.00 to $93.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an &#34;overweight&#34; rating on the biopharmaceutical company's stock. Morgan Stanley's target price would suggest a potential upside of 27.85% from the company's current price.</p>
<div class="lb-trans"><p>Halozyme Therapeutics（纳斯达克股票代码：HALO - 获取免费报告）在周二发布的一份报告中，摩根士丹利的研究分析师将其目标价格从 96.00 美元下调至 93.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “增持” 评级。摩根士丹利的目标价格暗示该公司当前价格有 27.85% 的潜在上涨空间。</p>
</div><p>Get <strong>Halozyme Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Halozyme Therapeutics</strong> 的提醒：</p>
</div><p>A number of other research firms also recently weighed in on HALO. Wells Fargo &amp; Company increased their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Thursday, February 19th. HC Wainwright increased their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, April 29th. Wall Street Zen downgraded shares of Halozyme Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, February 21st. TD Cowen reaffirmed a &#34;buy&#34; rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Finally, Benchmark increased their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, February 19th. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of &#34;Hold&#34; and an average price target of $80.67.</p>
<div class="lb-trans"><p>其他一些研究公司也最近对 HALO 发表了看法。富国银行将 Halozyme Therapeutics 的股票目标价格从 65.00 美元上调至 75.00 美元，并在 2 月 19 日的研究报告中给予该股票 “持平” 评级。HC Wainwright 将 Halozyme Therapeutics 的股票目标价格从 90.00 美元上调至 95.00 美元，并在 4 月 29 日的研究报告中给予该股票 “买入” 评级。华尔街 Zen 在 2 月 21 日的研究报告中将 Halozyme Therapeutics 的股票评级从 “强力买入” 下调至 “持有”。TD Cowen 在 2 月 18 日的研究报告中重申了对 Halozyme Therapeutics 的 “买入” 评级。最后，Benchmark 在 2 月 19 日的研究报告中将 Halozyme Therapeutics 的股票目标价格从 75.00 美元上调至 90.00 美元，并给予该股票 “买入” 评级。六位股票研究分析师对该股票给予了 “买入” 评级，五位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，Halozyme Therapeutics 目前的平均评级为 “持有”，平均目标价格为 80.67 美元。</p>
</div><p><strong>View Our Latest Research Report on HALO</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 HALO 的最新研究报告</strong></p>
</div><h2>Halozyme Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 股票表现</h2>
</div><p>Halozyme Therapeutics stock traded up $6.33 during midday trading on Tuesday, hitting $72.74. 2,175,469 shares of the company's stock were exchanged, compared to its average volume of 1,740,726. Halozyme Therapeutics has a 12-month low of $47.50 and a 12-month high of $82.22. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66. The stock has a market cap of $8.62 billion, a price-to-earnings ratio of 29.22, a price-to-earnings-growth ratio of 0.26 and a beta of 0.89. The firm's 50 day simple moving average is $65.68 and its 200 day simple moving average is $68.57.</p>
<div class="lb-trans"><p>Halozyme Therapeutics 的股票在周二的午盘交易中上涨了 6.33 美元，达到了 72.74 美元。该公司交易了 2,175,469 股股票，而其平均交易量为 1,740,726 股。Halozyme Therapeutics 的 12 个月低点为 47.50 美元，12 个月高点为 82.22 美元。该公司的债务与股本比率为 43.89，速动比率为 3.66，流动比率为 4.66。该股票的市值为 86.2 亿美元，市盈率为 29.22，市盈增长比率为 0.26，贝塔值为 0.89。该公司的 50 日简单移动平均线为 65.68 美元，200 日简单移动平均线为 68.57 美元。</p>
</div><p>Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts' consensus estimates of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The firm's revenue was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts predict that Halozyme Therapeutics will post 7.68 EPS for the current year.</p>
<div class="lb-trans"><p>Halozyme Therapeutics（纳斯达克股票代码：HALO - 获取免费报告）最近于 5 月 11 日发布了季度财报。这家生物制药公司报告本季度每股收益为 1.60 美元，超出分析师一致预期的 1.54 美元，超出幅度为 0.06 美元。该公司本季度的收入为 3.7671 亿美元，而一致预期为 3.5860 亿美元。Halozyme Therapeutics 的净利润率为 22.69%，股本回报率为 136.12%。该公司的收入同比增长了 42.2%。在去年同期，该公司每股收益为 1.11 美元。Halozyme Therapeutics 已将其 2026 财年的指导目标设定为每股收益 7.750-8.250 美元。股票研究分析师预测 Halozyme Therapeutics 在当前年度将发布每股收益 7.68 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company's stock, valued at approximately $49,322,187.20. The trade was a 2.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the transaction, the director directly owned 38,498 shares of the company's stock, valued at $2,443,853.04. This trade represents a 4.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 90,482 shares of company stock valued at $6,073,942. Company insiders own 2.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Helen Torley 在 4 月 2 日的交易中出售了 20,000 股 Halozyme Therapeutics 的股票。该股票以平均价格 64.24 美元出售，总价值为 1,284,800.00 美元。交易完成后，首席执行官直接持有该公司 767,780 股股票，价值约为 49,322,187.20 美元。此次交易使其持股减少了 2.54%。该交易已在向 SEC 提交的文件中披露，可以通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 Bernadette Connaughton 在 5 月 1 日的交易中出售了 1,625 股 Halozyme Therapeutics 的股票。该股票以平均价格 63.48 美元出售，总交易额为 103,155.00 美元。交易完成后，该董事直接持有该公司 38,498 股股票，价值为 2,443,853.04 美元。这笔交易使其持股减少了 4.05%。此次出售的披露信息可在 SEC 文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去三个月中，内部人士出售了价值 6,073,942 美元的 90,482 股公司股票。公司内部人士持有该公司股票的 2.50%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of HALO. Measured Wealth Private Client Group LLC boosted its stake in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 124 shares during the period. Abel Hall LLC raised its position in shares of Halozyme Therapeutics by 4.2% during the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company's stock worth $216,000 after buying an additional 129 shares in the last quarter. StoneX Group Inc. raised its position in shares of Halozyme Therapeutics by 3.8% during the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company's stock worth $246,000 after buying an additional 132 shares in the last quarter. Moran Wealth Management LLC raised its position in shares of Halozyme Therapeutics by 0.4% during the 4th quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company's stock worth $2,396,000 after buying an additional 151 shares in the last quarter. Finally, Twin Capital Management Inc. raised its position in shares of Halozyme Therapeutics by 1.4% during the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company's stock worth $738,000 after buying an additional 161 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近调整了对 Halozyme 的持股。Measured Wealth Private Client Group LLC 在第四季度将其在 Halozyme Therapeutics 的股份增加了 51.5%。Measured Wealth Private Client Group LLC 现在拥有 365 股该生物制药公司的股票，价值 25,000 美元，在此期间又购买了 124 股。Abel Hall LLC 在第四季度将其在 Halozyme Therapeutics 的股份提高了 4.2%。Abel Hall LLC 现在拥有 3,216 股该生物制药公司的股票，价值 216,000 美元，在上个季度又购买了 129 股。StoneX Group Inc. 在第四季度将其在 Halozyme Therapeutics 的股份提高了 3.8%。StoneX Group Inc. 现在拥有 3,650 股该生物制药公司的股票，价值 246,000 美元，在上个季度又购买了 132 股。Moran Wealth Management LLC 在第四季度将其在 Halozyme Therapeutics 的股份提高了 0.4%。Moran Wealth Management LLC 现在拥有 35,596 股该生物制药公司的股票，价值 2,396,000 美元，在上个季度又购买了 151 股。最后，Twin Capital Management Inc. 在第一季度将其在 Halozyme Therapeutics 的股份提高了 1.4%。Twin Capital Management Inc. 现在拥有 11,422 股该生物制药公司的股票，价值 738,000 美元，在上个季度又购买了 161 股。97.79% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>More Halozyme Therapeutics News</h2>
<div class="lb-trans"><h2>更多 Halozyme Therapeutics 新闻</h2>
</div><p>Here are the key news stories impacting Halozyme Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本周影响 Halozyme Therapeutics 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Halozyme beat first-quarter expectations on both revenue and earnings, with revenue up 42% year over year to about $377 million and EPS of $1.60 topping estimates. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE</li>
<li>Positive Sentiment: The company also announced a new $1 billion share repurchase program and said it expects to buy back at least $400 million in 2026, signaling confidence in cash flow and future performance. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE</li>
<li>Neutral Sentiment: Halozyme reiterated full-year 2026 guidance for revenue, adjusted EBITDA, and non-GAAP EPS, which suggests management remains confident but did not raise its outlook despite the beat. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE</li>
<li>Negative Sentiment: Some third-party summaries highlighted that diluted EPS came in below certain estimates, even though revenue was strong, which may temper enthusiasm around the quarter. Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Halozyme 在第一季度的收入和收益均超出预期，收入同比增长 42%，约为 3.77 亿美元，EPS 为 1.60 美元，超出预期。HALOZYME 报告 2026 年第一季度业绩并重申 2026 年财务指引</li>
<li>积极情绪：该公司还宣布了一项新的 10 亿美元股票回购计划，并表示预计在 2026 年回购至少 4 亿美元的股票，显示出对现金流和未来表现的信心。HALOZYME 报告 2026 年第一季度业绩并重申 2026 年财务指引</li>
<li>中性情绪：Halozyme 重申了 2026 年的全年收入、调整后 EBITDA 和非 GAAP EPS 指引，这表明管理层仍然充满信心，但尽管业绩超出预期，仍未提高其前景。HALOZYME 报告 2026 年第一季度业绩并重申 2026 年财务指引</li>
<li>消极情绪：一些第三方摘要指出，稀释后的 EPS 低于某些预期，尽管收入强劲，这可能会抑制对本季度的热情。Halozyme Therapeutics, Inc. (HALO) 2026 年第一季度财报电话会议记录</li>
</ul>
</div><h2>Halozyme Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.</p>
<div class="lb-trans"><p>Halozyme Therapeutics, Inc. 是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，专注于新型药物输送技术的开发和商业化。成立于 1998 年，Halozyme 专注于通过其专有平台实现生物治疗的皮下给药。公司的核心使命是改善患者的获取和便利性，同时保持与传统给药途径相当或更好的疗效和安全性。</p>
</div><p>The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.</p>
<div class="lb-trans"><p>公司的旗舰技术 ENHANZE® 基于重组人透明质酸酶 PH20 (rHuPH20)，这是一种在细胞外基质中暂时降解透明质酸的酶。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Halozyme Therapeutics</li>
<li>Shake Shack Stock Gets Shaken After Earnings Miss</li>
<li>On Holdings Sets Up for Marathon Rally: New Highs Are Coming</li>
<li>The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000</li>
<li>MP Materials Is Quietly Building a Rare Earth Powerhouse</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Halozyme Therapeutics</li>
<li>Shake Shack 股票因业绩不及预期而受到冲击</li>
<li>On Holdings 为马拉松反弹做好准备：新高即将到来</li>
<li>DRAM 震荡：三星失足，美光追逐 1000 美元</li>
<li>MP Materials 正在悄然建立一个稀土强国</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SEFMTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=HALO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Halozyme Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Halozyme Therapeutics 吗？</h2>
</div><p>Before you consider Halozyme Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Halozyme Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Halozyme Therapeutics 并不在名单上。</p>
</div><p>While Halozyme Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Halozyme Therapeutics 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Morgan Stanley Cuts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00

Market Beat

Invesco Nasdaq Biotechnology ETF

摩根士丹利

富国银行

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

摩根士丹利将奥洛兹美医疗（NASDAQ:HALO）的目标股价下调至 93.00 美元